CNMDHIGH SIGNALFINANCIAL10-K

CNMD experienced a dramatic 64.5% collapse in net income despite increased capital investment, with operating income falling 48.8% while SG&A expenses surged 23.8%.

The severe profitability decline combined with rising expenses suggests significant operational challenges or one-time charges that materially impacted performance. The company appears to be investing in growth (higher capex) while struggling with cost control and margin compression, raising questions about management execution and competitive positioning.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

CNMD's financial performance deteriorated sharply with net income plummeting from $132.4M to $47.1M and operating income falling from $200.3M to $102.6M, while SG&A expenses ballooned by nearly $114M. Despite these profitability challenges, the company increased capital expenditures by 51% and grew cash reserves by 48%, suggesting either strategic investment during a difficult period or potential asset sales. The combination of collapsing earnings, rising costs, and increased liabilities points to a company under significant financial stress that may be investing for a turnaround.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-64.5%
$132.4M$47.1M

Net income declined 64.5% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
+51.4%
$13.1M$19.8M

Capital expenditure jumped 51.4% — major investment cycle underway; assess returns on deployment.

Operating Income
P&L
-48.8%
$200.3M$102.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
+47.7%
$17.5M$25.9M

Cash position surged 47.7% — strong cash generation or capital raise providing significant financial cushion.

SG&A Expense
P&L
+23.8%
$478.3M$592.0M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Current Liabilities
Balance Sheet
+13.3%
$278.1M$315.0M

Current liabilities rose 13.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 7A.
Substantially all of our facilities have attained certification under the International Organization for Standardization ("ISO") international quality standards and other domestic and international quality accreditations.
We also pursue organic growth by focusing on our differentiated products.
These products allow us to reach more surgeons and physicians and in turn also introduce other products in our portfolios.
During our assessment, we may also identify products that no longer align with our strategy and therefore may discontinue or divest such products to focus on portfolio optimization, reallocate capital to grow meaningful innovation, and expand margins.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 7A.
Substantially all of our facilities have attained certification under the ISO international quality standards and other domestic and international quality accreditations.
We compete with Smith Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson Johnson: DePuy Mitek, Inc.; Zimmer Biomet, Inc.; Paragon 28, Inc.
In 2024, approximately 77% of orthopedic surgery revenue came from single-use products that are expected to be recurring.
In addition to these offerings, we offer a unique energy platform specifically designed for gastroenterology and pulmonology procedures.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →